<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vardenafil: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vardenafil: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Vardenafil: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11233" href="/d/html/11233.html" rel="external">see "Vardenafil: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F233465"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Levitra [DSC];</li>
<li>Staxyn [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868573"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Vardenafil;</li>
<li>JAMP-Vardenafil;</li>
<li>JAMP-Vardenafil ODT;</li>
<li>Levitra [DSC];</li>
<li>MYLAN-VARDENAFIL;</li>
<li>Staxyn [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F233485"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Phosphodiesterase-5 Enzyme Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F233468"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Oral disintegrating tablets should not be used interchangeably with film-coated tablets; patients requiring a dose other than 10 mg should use the film-coated tablets.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="77b945d9-a93d-48b1-8ab3-46e494efb128">Erectile dysfunction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Erectile dysfunction:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Film-coated tablet (Levitra): <b>Oral: </b>10 mg administered ~60 minutes prior to sexual activity; dosing range: 5 to 20 mg as a single dose (not more than once daily); maximum: 20 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral disintegrating tablet (Staxyn): <b>Oral: </b>10 mg administered ~60 minutes prior to sexual activity; maximum: 10 mg/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9b6777ad-1508-4cf7-924a-99d10f0a73e1">Pulmonary arterial hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary arterial hypertension</b>
<b> (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consult a pulmonary arterial hypertension specialist for all management decisions; choice of therapy is dependent on etiology, risk stratification, and cardiopulmonary comorbidities. Vardenafil is contraindicated in patients taking riociguat due to potentially severe hypotension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30660783','lexi-content-ref-36017548']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30660783','lexi-content-ref-36017548'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 5 mg once daily for 4 weeks, then increase to target dose of 5 mg twice daily if tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21471085']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21471085'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fed0e48d-298d-453f-bda8-97189c608a2d">Raynaud phenomenon</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Raynaud phenomenon (off-label use):</b>
<b>Oral:</b> 10 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16432094','lexi-content-ref-22710940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16432094','lexi-content-ref-22710940'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult Drug Interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990270"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild, moderate, or severe impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Use is not recommended.</p></div>
<div class="block doha drugH1Div" id="F50987469"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Erectile dysfunction: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate impairment (Child-Pugh class B):</p>
<p style="text-indent:-2em;margin-left:6em;">Film-coated tablet (Levitra): <b>Oral: </b>Initial: 5 mg administered ~60 minutes prior to sexual activity (maximum: 10 mg/day).</p>
<p style="text-indent:-2em;margin-left:6em;">Oral disintegrating tablet (Staxyn): Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (Child-Pugh class C): Use is not recommended (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F233469"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">
<b>Erectile dysfunction:</b> Film-coated tablet (Levitra): <b>Oral:</b> Consider a lower initial dose of 5 mg administered ~60 minutes prior to sexual activity.</p></div>
<div class="block adr drugH1Div" id="F233435"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (8% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (14% to 15%)</p>
<p style="text-indent:-2em;margin-left:2em;">2% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dizziness (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (3% to 4%), nausea (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (2%), increased creatine phosphokinase (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Rhinitis (9%), flu-like symptoms (3%), nasal congestion (3%), sinusitis (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;2%, postmarketing, and/or case reports: Abdominal pain, abnormal hepatic function tests, allergic edema, anaphylaxis, angina pectoris, angioedema, arthralgia, auditory impairment, basal cell carcinoma (Loeb 2015), blurred vision, chest pain, chromatopsia, conjunctivitis, decreased visual acuity, diaphoresis, diarrhea, drowsiness, dysesthesia, dysphagia, dyspnea, ejaculatory disorder, epistaxis, erythema, esophagitis, eye discomfort, eye pain, facial edema, gastritis, gastroesophageal reflux disease, glaucoma, hearing loss, hypersensitivity reaction, hypertension, hypertonia, hypoesthesia, hypotension, increased gamma-glutamyl transferase, increased intraocular pressure, insomnia, ischemic heart disease, laryngeal edema, malignant melanoma (Loeb 2015), muscle cramps, myalgia, myocardial infarction, neck pain, anterior ischemic optic neuropathy (nonarteritic; NAION), ocular hyperemia, orthostatic hypotension, pain, palpitations, paresthesia, pharyngitis, photophobia, priapism, pruritus, retinal vein occlusion, seizure, skin photosensitivity, skin rash, sleep disorder, syncope, tachycardia, temporary amnesia (global), tinnitus, ventricular tachyarrhythmia, vertigo, vision color changes, vision loss (temporary or permanent), visual disturbance (including dim vision), visual field defect, vomiting, watery eyes, weakness, xerostomia</p></div>
<div class="block coi drugH1Div" id="F233449"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Coadministration with nitrates (either regularly and/or intermittently), nitric oxide donors, or guanylate cyclase stimulators (eg, riociguat).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to vardenafil or any component of the formulation; concomitant use with cobicistat, indinavir, ritonavir, saquinavir, atazanavir, ketoconazole or itraconazole (Levitra, Staxyn), and erythromycin or clarithromycin (Staxyn); prior episode of non-arteritic anterior ischemic optic neuropathy.</p></div>
<div class="block war drugH1Div" id="F233433"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Color discrimination: May cause dose-related impairment of visual color discrimination (blue/green).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hearing loss: Sudden decrease or loss of hearing has been reported rarely; hearing changes may be accompanied by tinnitus and dizziness. A direct relationship between therapy and hearing loss has not been determined.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension: Decreases in blood pressure may occur due to vasodilator effects. Use with caution in patients with left ventricular outflow obstruction (aortic stenosis or hypertrophic cardiomyopathy with outflow tract obstruction); may be more sensitive to hypotensive actions. Concurrent use with alpha-adrenergic antagonist therapy may cause symptomatic hypotension; ensure hemodynamic stability prior to initiating film-coated tablets and use the lowest possible dose; do not initiate oral disintegrating tablet in patients taking alpha-adrenergic antagonists. Avoid or limit concurrent substantial ethanol consumption as this may increase the risk of symptomatic hypotension.</p>
<p style="text-indent:-2em;margin-left:4em;">• Priapism: Painful erection &gt;6 hours in duration has been reported (rarely). Instruct patients to seek immediate medical attention if erection persists &gt;4 hours. Use with caution in patients who have conditions which may predispose them to priapism (sickle cell anemia, multiple myeloma, leukemia).</p>
<p style="text-indent:-2em;margin-left:4em;">• Vision loss: Vision loss may occur rarely and be a sign of non-arteritic anterior ischemic optic neuropathy (NAION). Instruct patients to seek medical assistance for sudden loss of vision in one or both eyes. Patients who have already experienced NAION are at an increased risk of recurrence. Other risk factors for NAION include low cup-to-disc ratio (“crowded disc”), coronary artery disease, diabetes, hypertension, hyperlipidemia, smoking, and age &gt;50 years; use with caution and only when the benefits outweigh the risks in these patients. Safety and efficacy were not studied in patients with known degenerative retinal disorders (eg, retinitis pigmentosa); use is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anatomical penis deformation: Use with caution in patients with anatomical deformation of the penis (angulation, cavernosal fibrosis, or Peyronie disease).</p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding disorders: Use with caution in patients with bleeding disorders; safety and efficacy have not been established.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use is not recommended in patients with hypotension (resting systolic BP &lt;90 mm Hg); uncontrolled hypertension (&gt;170/100 mm Hg); unstable angina or angina during intercourse; life-threatening arrhythmias, stroke, or MI within the last 6 months; cardiac failure or coronary artery disease causing unstable angina. Safety and efficacy have not been studied in these patients. Use caution in patients with left ventricular outflow obstruction (eg, aortic stenosis, hypertrophic cardiomyopathy with outflow tract obstruction). There is a degree of cardiac risk associated with sexual activity; therefore, physicians may wish to consider the cardiovascular status of their patients prior to initiating any treatment for erectile dysfunction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Congenital or acquired QT prolongation: Not recommended for use in patients with congenital or acquired (ie, medication induced) QT prolongation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with moderate hepatic impairment (Child-Pugh class B); dosage adjustment is needed. Safety and efficacy have not been studied in patients with severe hepatic impairment (Child-Pugh class C); therefore, use in these patients is not recommended. Per the manufacturer, the oral disintegrating tablet should not be used in patients with moderate to severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peptic ulcer disease: Use with caution in patients with active peptic ulcer disease; safety and efficacy have not been established.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Safety and efficacy have not been studied in patients with end-stage renal disease requiring dialysis; therefore, use in these patients is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Nitrates: Concomitant use with all forms of nitrates is contraindicated. If nitrate administration is medically necessary, it is not known when nitrates can be safely administered following the use of vardenafil; however, when a 20 mg (film-coated tablet) was administered 24 hours prior to a 0.4 mg sublingual dose of nitroglycerin, no changes in blood pressure or heart rate were detected.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in older adults; dosage reduction may be necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Phenylalanine: Some products may contain phenylalanine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sorbitol: Some products may contain sorbitol; do not use in patients with fructose intolerance.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Potential underlying causes of erectile dysfunction should be evaluated prior to treatment.</p></div>
<div class="block foc drugH1Div" id="F233443"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Levitra: 10 mg [DSC], 20 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg, 10 mg, 20 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Staxyn: 10 mg [DSC] [contains aspartame; peppermint flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg</p></div>
<div class="block geq drugH1Div" id="F233430"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F233450"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, orally-disintegrating</b> (Vardenafil HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $36.18</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Vardenafil HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $55.56 - $58.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $55.56 - $58.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $55.56 - $58.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $55.56 - $58.72</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868574"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Levitra: 5 mg [DSC], 10 mg [DSC], 20 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg, 20 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Staxyn: 10 mg [DSC] [contains aspartame]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg</p></div>
<div class="block adm drugH1Div" id="F233446"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">May be administered with or without food, approximately 60 minutes prior to sexual activity.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral disintegrating tablet should not be removed from blister pack until administered. Using dry hands, place immediately on tongue. Tablet will dissolve rapidly; do not take with liquid. Do not crush, split, or chew.</p></div>
<div class="block use drugH1Div" id="F233445"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Erectile dysfunction:</b> Treatment of erectile dysfunction.</p></div>
<div class="block off-label drugH1Div" id="F46914133"><span class="drugH1">Use: Off-Label: Adult</span><p>Pulmonary arterial hypertension; Raynaud phenomenon</p></div>
<div class="block mst drugH1Div" id="F233493"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vardenafil may be confused with sildenafil, tadalafil</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Levitra may be confused with Kaletra, Lexiva</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F233479"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F233437"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Blockers (Nonselective): Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Alpha1-Blockers (Nonselective).  Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Blockers (Uroselective): May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alprostadil: Phosphodiesterase 5 Inhibitors may enhance the adverse/toxic effect of Alprostadil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amyl Nitrite: Phosphodiesterase 5 Inhibitors may enhance the vasodilatory effect of Amyl Nitrite. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosentan: May decrease the serum concentration of Phosphodiesterase 5 Inhibitors. Phosphodiesterase 5 Inhibitors may increase the serum concentration of Bosentan.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: May increase the serum concentration of Vardenafil. Management: Limit the dose of vardenafil tablets to a single 2.5 mg dose within a 72-hour period if combined with cobicistat. Avoid concomitant use of vardenafil orally disintegrating tablets and cobicistat. Combined use is contraindicated outside of the US.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Vardenafil. Management: Limit Levitra (vardenafil) dose to a single 5 mg dose within a 24-hour period if combined with moderate CYP3A4 inhibitors. Avoid concomitant use of Staxyn (vardenafil) and moderate CYP3A4 inhibitors. Combined use is contraindicated outside of the US.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Vardenafil. Management: Limit Levitra (vardenafil) dose to a single 2.5 mg dose within a 24-hour period if combined with strong CYP3A4 inhibitors. Avoid concomitant use of Staxyn (vardenafil) and strong CYP3A4 inhibitors. Combined use is contraindicated outside of the US.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the orthostatic hypotensive effect of Phosphodiesterase 5 Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: May decrease the serum concentration of Phosphodiesterase 5 Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: May increase the serum concentration of Vardenafil. Management: Limit Levitra (vardenafil) dose to 5 mg per 24 hours with itraconazole 200 mg/day and 2.5 mg per 24 hours with itraconazole 400 mg/day. Avoid concomitant use of Staxyn (vardenafil) and itraconazole. Combined use is contraindicated outside of the US.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): May increase the serum concentration of Vardenafil. Management: Limit Levitra (vardenafil) dose to 5 mg per 24 hours with ketoconazole 200 mg/day and 2.5 mg per 24 hours with ketoconazole 400 mg/day. Avoid concomitant use of Staxyn (vardenafil) and ketoconazole. Combined use is contraindicated outside of the US.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorcaserin (Withdrawn From US Market): May enhance the adverse/toxic effect of Phosphodiesterase 5 Inhibitors. Specifically, the risk of developing priapism may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of Vardenafil. Management: Limit the dose of vardenafil tablets to a single 2.5 mg dose within a 72-hour period if combined with nirmatrelvir/ritonavir. Avoid concomitant use of vardenafil orally disintegrating tablets and nirmatrelvir/ritonavir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Nitroprusside. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the adverse/toxic effect of other Phosphodiesterase 5 Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Riociguat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May increase the serum concentration of Vardenafil. Management: Limit the dose of vardenafil tablets to a single 2.5 mg dose within a 72-hour period if combined with ritonavir. Avoid concomitant use of vardenafil orally disintegrating tablets and ritonavir. Combined use is contraindicated outside of the US.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sapropterin: May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: May increase the serum concentration of Phosphodiesterase 5 Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vasodilators (Organic Nitrates): Phosphodiesterase 5 Inhibitors may enhance the vasodilatory effect of Vasodilators (Organic Nitrates). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vericiguat: May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.<i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F233462"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">High-fat meals decrease maximum serum concentration 18% to 50%. Serum concentrations/toxicity may be increased with grapefruit juice. Management: Do not take with a high-fat meal. Monitor for increased effects/toxicity with concomitant grapefruit consumption.</p></div>
<div class="block rep_considerations drugH1Div" id="F53632819"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">No effects on sperm motility or morphology were observed in healthy males; increased sperm count and motility were observed in patients with oligozoospermia (Drobnis 2017).</p></div>
<div class="block pri drugH1Div" id="F233451"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were not observed in animal reproduction studies.</p>
<p style="text-indent:0em;margin-top:2em;">Vardenafil has been evaluated for the treatment of pulmonary arterial hypertension (PAH) (Jing 2011). Untreated PAH in pregnancy increases the risk for heart failure, stroke, preterm delivery, and maternal/fetal death. Patients with PAH are encouraged to avoid becoming pregnant (ACCP [Klinger 2019]; Hemnes 2015). If treatment with a phosphodiesterase-5 enzyme inhibitor is needed for the treatment of PAH during pregnancy, agents other than vardenafil are suggested (ESC [Regitz-Zagrosek 2018], Hemnes 2015).</p></div>
<div class="block brc drugH1Div" id="F18881612"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if vardenafil is present in breast milk.</p></div>
<div class="block dic drugH1Div" id="F233452"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain phenylalanine. Some products may contain sorbitol; do not use in patients with fructose intolerance.</p></div>
<div class="block mop drugH1Div" id="F233441"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor BP, heart rate, signs/symptoms of orthostasis; visual impairment (eg, vision loss, cyanopsia); hearing impairment; prolonged erection and/or priapism.</p></div>
<div class="block pha drugH1Div" id="F233432"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Does not directly cause penile erections, but affects the response to sexual stimulation. The physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. NO then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation and inflow of blood to the corpus cavernosum. Vardenafil enhances the effect of NO by inhibiting phosphodiesterase type 5 (PDE-5), which is responsible for degradation of cGMP in the corpus cavernosum; when sexual stimulation causes local release of NO, inhibition of PDE-5 by vardenafil causes increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the corpus cavernosum; at recommended doses, it has no effect in the absence of sexual stimulation.</p></div>
<div class="block phk drugH1Div" id="F233448"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: ~60 minutes</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Rapid</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 208 L</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: ~95% (parent drug and metabolite)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic via CYP3A4 (major), CYP2C and 3A5 (minor); forms metabolite (active)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: ~15%</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Film-coated tablet: Elderly (≥65 years): AUC increased by 52%; Hepatic impairment (moderate, Child-Pugh class B): AUC increased by 160%</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Oral disintegrating tablet: Elderly (≥65 years): AUC increased by 21% more compared to film-coated tablet. When administered with water, AUC decreases by 29%.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Terminal: Vardenafil and metabolite: 4 to 6 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, plasma: 0.5 to 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (~91% to 95% as metabolites); urine (~2% to 6%)</p></div>
<div class="block phksp drugH1Div" id="F51204423"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: The AUC was 20% to 30% higher in moderate (CrCl 30 to 50 mL/minute) and severe (CrCl &lt;30 mL/minute) renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: In patients with mild hepatic impairment (Child-Pugh class A), C<sub>max</sub> and AUC increased by 22% and 17%, respectively. In patients with moderate hepatic impairment (Child-Pugh class B), C<sub>max</sub> and AUC increased by 130% and 160%, respectively.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: In men ≥65 years of age, the C<sub>max</sub> and AUC are increased 34% and 52%, respectively, for Levitra and by 21% and 39%, respectively, for Staxyn compared with men &lt;45 years.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F233453"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Lexta | X pert</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Levitra</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Vardenafil 1a pharma | Vardenafil rivopharm | Vardenafil sandoz | Vardenafil stada | Vardenaristo | Vivanza</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Levitra</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Vardenafil krka | Vardenafil sandoz | Vivanza</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Vardenafil</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Vivanza</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Vardenafil mepha | Vivanza</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Levitra</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Levitra</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Xoxaxin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Levitra</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Vardegin | Vardenafil 1a pharma | Vardenafil abz | Vardenafil holsten | Vardenafil neuraxpharm | Vardenafil zentiva | Vardenaristo | Vivanza</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Levitra</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Varfil</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Vardegin | Vardenafil actavis | Vardenafil sandoz | Vardenafil sanoswiss</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Dispatigra | Erectnapofil | Farorecta | Levitra | Powerecta | Rapidoverd | Romantigra | Rowadinafil | Solvetra | Vardarict | Vardatrin | Vardection | Vardena | Vardirose | Varnova | Verdenodeb | Vigafil | Vivanza | Westrecta</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Levatik | Levitra | Sarilen | Vardenafilo | Vardenafilo aristo | Vardenafilo aurovitas | Vardenafilo cinfa | Vardenafilo flas stadagen | Vardenafilo krka | Vardenafilo pensa | Vardenafilo qualigen | Vardenafilo ratiopharm | Vardenafilo stada | Vardenafilo tecnigen | Vardenafilo teva | Vivanza</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Vardenafil accord | Vardenafil krka | Vardenafil stada</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Vardenafil accord | Vardenafil biogaran | Vardenafil krka | Vardenafil mylan | Vardenafil sandoz</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Vardenafil | Vardenafil accord | Vardenafil aristo | Vardenafil mylan | Vardenafil zentiva</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Vivanza</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Levitra</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Levitra</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Vardenafil rivopharm</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Levitra</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Levitra</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Levitra</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Edafil | Levifil | Valif | Varimax | Vilitra</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Horse man</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Elutatis | Levitra | Vardenafil | Vardenafil accord | Vardenafil aristo | Vardenafil aristo pharma | Vardenafil doc | Vardenafil eg | Vardenafil krka | Vardenafil mylan | Vardenafil pensa | Vardenafil sandoz | Vardenafil tecnigen | Vardenafil zentiva | Vivanza</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Levitra</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Vardenafil fci</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Varnil</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Yaila</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Levitra | X pert</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Levitra</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Vardenafil sanoswiss</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Vivanza</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Vardenafil actavis | Vardenafil sandoz | Vardenafil sanoswiss | Viavardis</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Levitra</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Levitra</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Levitra</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Vardenafil accord | Vardenafil teva</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Vardenafil aristo | Vardenafil krka</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Vardenafil</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Levitra</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Vardenafil</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Vardenafil accord | Viavardis</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Staxyn</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Vardenafil | Vardenafil aristo | Vardenafil ciclum | Vardenafil generis | Vardenafil krka | Vardenafil tolife</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Eroxil | Novopramil | Vardemax | Vardenafil eticos</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Levitra ODT | X-pert D</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Levitra</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Vardenafil</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Devarin | Erevard | Levitra</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Vardenafil accord | Vardenafil aristo | Vardenafil krka | Vardenafil sanoswi | Vardenafil stada</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Levitra</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Viavardis</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Levitra</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Levitra</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Lovitrec</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Verticord</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Levitra</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Levitra</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Levitra</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Levina | Varafil</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Levitra | Varfydo fc</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-23630129">
<a name="23630129"></a>Anderson JL, Adams CD, Antman EM, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(23):e663-e828. doi:10.1161/CIR.0b013e31828478ac<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vardenafil-drug-information/abstract-text/23630129/pubmed" id="23630129" target="_blank">23630129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22710940">
<a name="22710940"></a>Caglayan E, Axmann S, Hellmich M, Moinzadeh P, Rosenkranz S. Vardenafil for the treatment of Raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. <i>Arch Intern Med</i>. 2012;172(15):1182-1184.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vardenafil-drug-information/abstract-text/22710940/pubmed" id="22710940" target="_blank">22710940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16432094">
<a name="16432094"></a>Caglayan E, Huntgeburth M, Karasch T, et al. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. <i>Arch Intern Med</i>. 2006;166(2):231-233.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vardenafil-drug-information/abstract-text/16432094/pubmed" id="16432094" target="_blank">16432094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9935041">
<a name="9935041"></a>Cheitlin MD, Hutter AM Jr, Brindis RG, et al. Use of Sildenafil (Viagra®) in Patients With Cardiovascular Disease. <i>J Am Coll Cardiol</i>. 1999;33(1):273-282.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vardenafil-drug-information/abstract-text/9935041/pubmed" id="9935041" target="_blank">9935041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29256125">
<a name="29256125"></a>Drobnis EZ, Nangia AK. Phosphodiesterase inhibitors (PDE inhibitors) and male reproduction. <i>Adv Exp Med Biol</i>. 2017;1034:29-38. doi:10.1007/978-3-319-69535-8_5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vardenafil-drug-information/abstract-text/29256125/pubmed" id="29256125" target="_blank">29256125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26401246">
<a name="26401246"></a>Hemnes AR, Kiely DG, Cockrill BA, et al. Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute. <i>Pulm Circ</i>. 2015;5(3):435-465. doi:10.1086/682230<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vardenafil-drug-information/abstract-text/26401246/pubmed" id="26401246" target="_blank">26401246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017548">
<a name="36017548"></a>Humbert M, Kovacs G, Hoeper MM, et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension.<i> Eur Heart J</i>. 2022;43(38):3618-3731. doi:10.1093/eurheartj/ehac237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vardenafil-drug-information/abstract-text/36017548/pubmed" id="36017548" target="_blank">36017548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16409215">
<a name="16409215"></a>Jackson G, Rosen RC, Kloner RA, et al. The Second Princeton Consensus on Sexual Dysfunction and Cardiac Risk: New Guidelines for Sexual Medicine. <i>J Sex Med</i>. 2006;3(1):28-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vardenafil-drug-information/abstract-text/16409215/pubmed" id="16409215" target="_blank">16409215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21471085">
<a name="21471085"></a>Jing ZC, Yu ZX, Shen JY, et al; Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension (EVALUATION) Study Group. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. <i>Am J Respir Crit Care Med</i>. 2011;183(12):1723-1729. doi:10.1164/rccm.201101-0093OC<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vardenafil-drug-information/abstract-text/21471085/pubmed" id="21471085" target="_blank">21471085</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30660783">
<a name="30660783"></a>Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report. <i>Chest</i>. 2019;155(3):565-586. doi:10.1016/j.chest.2018.11.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vardenafil-drug-information/abstract-text/30660783/pubmed" id="30660783" target="_blank">30660783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27941129">
<a name="27941129"></a>Kowal-Bielecka O, Fransen J, Avouac J, et al; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Ann Rheum Dis</i>. 2017;76(8):1327-1339. doi:10.1136/annrheumdis-2016-209909<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vardenafil-drug-information/abstract-text/27941129/pubmed" id="27941129" target="_blank">27941129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Levitra.1">
<a name="Levitra.1"></a>Levitra (vardenafil) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Levitra.2">
<a name="Levitra.2"></a>Levitra (vardenafil) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26103029">
<a name="26103029"></a>Loeb S, Folkvaljon Y, Lambe M, et al. Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma. <i>JAMA</i>. 2015;313(24):2449-2455.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vardenafil-drug-information/abstract-text/26103029/pubmed" id="26103029" target="_blank">26103029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18077811">
<a name="18077811"></a>McVary KT. Clinical Practice. Erectile Dysfunction. <i>N Engl J Med</i>. 2007;357(24):2472-2481.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vardenafil-drug-information/abstract-text/18077811/pubmed" id="18077811" target="_blank">18077811</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22862865">
<a name="22862865"></a>Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. <i>Mayo Clin Proc</i>. 2012;87(8):766-778. doi:10.1016/j.mayocp.2012.06.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vardenafil-drug-information/abstract-text/22862865/pubmed" id="22862865" target="_blank">22862865</a>]</span>
<span class="doi">10.1016/j.mayocp.2012.06.015</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(4):e362-e425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vardenafil-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vardenafil-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23426043">
<a name="23426043"></a>Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomized trials. <i>Ann Rheum Dis</i>. 2013;72(10):1696-1699.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vardenafil-drug-information/abstract-text/23426043/pubmed" id="23426043" target="_blank">23426043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Staxyn.1">
<a name="Staxyn.1"></a>Staxyn (vardenafil) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Staxyn.2">
<a name="Staxyn.2"></a>Staxyn (vardenafil) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; February 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 10172 Version 308.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
